Literature DB >> 15652200

Effect of adsorbents on the absorption of lansoprazole with surfactant.

Yukako Ito1, Harumi Arai, Kaori Uchino, Kouji Iwasaki, Nobuhito Shibata, Kanji Takada.   

Abstract

Lansoprazole (LPZ) is a representative drug that shows a high inter-subject variation of bioavailability (BA). Solid preparation composed of surfactant, adsorbent and LPZ were prepared to improve the dissolution and absorption of LPZ, and the BA of LPZ was measured in rats and dogs. As surfactant, Tween 80, polyoxy 60 hydrogenated caster oil derivative (HCO-60) and PEG-8 caprylic/capric glycerides (Labrasol) were used. As adsorbant, porous silicon dioxide (Sylysia 550, 320), magnesium aluminometa silicate (Neusilin S2, NS2N, US2) and porous calcium silicate (Florite RE) were used. After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C(max) and AUC was 0.46+/-0.01 microg/mL and 0.73+/-0.03 microgh/mL. By comparing to that after i.v. injection of LPZ solution, 2.0 mg/kg, the BA of LPZ from HCO-60 solution was 39.0%, which was about seven times higher than that of LPZ powder. To solidify the LPZ solution with HCO-60, adsorbents were used and the obtained solid preparations were used for in vitro release experiment. Sylysia 320, Neusilin S2 and Neusilin NS2 showed the T50% of about 1h. To evaluate the BA of these solid preparations, absorption study was performed in rats. Sylysia 550 system showed the higher AUC than other systems, showing the BA of 28.1%. Sylysia 550 system was filled in an enteric capsule and was orally administered to dogs and BA was compared with enteric tablet. The AUC of Sylysia 550 system was 2.16+/-0.26 microgh/mL and was greater than enteric tablet and the BA of 71.7% was obtained. Solid system composed of LPZ, surfactant and adsorbent has suggested the possibility as a good tool to improve the BA of LPZ.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15652200     DOI: 10.1016/j.ijpharm.2004.10.010

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Influence of formulation factors on tablet formulations with liquid permeation enhancer using factorial design.

Authors:  Naveen K Bejugam; Helen J Parish; Gita N Shankar
Journal:  AAPS PharmSciTech       Date:  2009-12-01       Impact factor: 3.246

2.  Preparation and evaluation of enteric coated tablets of hot-melt extruded lansoprazole.

Authors:  Bader B Alsulays; Vijay Kulkarni; Sultan M Alshehri; Bjad K Almutairy; Eman A Ashour; Joseph T Morott; Abdullah S Alshetaili; Jun-Bom Park; Roshan V Tiwari; Michael A Repka
Journal:  Drug Dev Ind Pharm       Date:  2016-08-21       Impact factor: 3.225

3.  Development of Solid SEDDS, IV: Effect of Adsorbed Lipid and Surfactant on Tableting Properties and Surface Structures of Different Silicates.

Authors:  Suhas G Gumaste; Sara A Pawlak; Damon M Dalrymple; Charles J Nider; Louis D Trombetta; Abu T M Serajuddin
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

4.  Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation.

Authors:  Sameer Sharma; Praveen Sher; Shraddha Badve; Atmaram P Pawar
Journal:  AAPS PharmSciTech       Date:  2005-12-07       Impact factor: 3.246

5.  Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modeling.

Authors:  Yi Lu; Tao Guo; Jianping Qi; Jiwen Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2012-09-12       Impact factor: 3.246

6.  Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.

Authors:  Milind Alai; Wen Jen Lin
Journal:  AAPS J       Date:  2014-02-12       Impact factor: 4.009

7.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

8.  Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations.

Authors:  Milind Alai; Wen Jen Lin
Journal:  Int J Nanomedicine       Date:  2015-06-18

9.  Preformulation studies on solid self-emulsifying systems in powder form containing magnesium aluminometasilicate as porous carrier.

Authors:  Anna Krupa; Jakub Szlęk; Benedykt R Jany; Renata Jachowicz
Journal:  AAPS PharmSciTech       Date:  2014-12-11       Impact factor: 3.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.